Our Latest Patented Technology:
Liqui-SRS®
IP protected by Umbrella Patent EP4445899A1 for a wide range of APIs and indications across therapeutic categories making Liqui-SRS® a platform-technology in the true-sense of the term.
Liqui-SRS® is a 2-Step Approach to provide SR properties to low soluble APIs.
1. Enhancing Solubility of API
2. Formulating Galenical Sustained Release Product
Potential Applications of Liqui-SRS® :
1. SR / XR benefits to low soluble APIs.
2. Life-cycle-management of Critical Products containing low soluble APIs.
3. Innovative Products / New Discoveries: Liqui-SRS® leading on a pathway of potentially Novel First-time-SR Formulations of a wide range of APIs across Therapeutic Categories.
4. Clinical Profiling of low soluble generic APIs.
5. Improved BA/BE performance of low soluble APIs as SR.
6. Potentially improved Access-to-Medication / provides opportunity to tap the unmet patient needs Globally.
7. ROI of Development Costs for new Drug Products.
Interested?
We can grant a license to the technology for your low soluble API with SR / XR requirements after performing proof-of-concept in our Lab.
Please send inquiries to info@emoviar.de
OR
contact by phone +49 7762 8179863